Paper Details

  1. Home
  2. Paper Details

Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.

Author: AhmedMalik Qistas, AkbarArshia, AnjumAhmad, AnwerFaiz, AshrafAqsa, DeanRobert, FaisalMuhammad Salman, FarooqTalha Bin, FarooquiArafat Ali, KanateAbraham, NabeelShaha, RehmanSaif Ur, TariqMuhammad Junaid

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This review focuses on the safety and efficacy of novel targeted therapies for chronic lymphocytic leukemia (CLL), particularly in elderly patients. The review highlights the increasing use of agents targeting dysregulated pathways, such as BCR inhibitors, PI3K inhibitors, spleen tyrosine kinase inhibitors, Bcl-2 inhibitors, immunomodulators, and monoclonal antibodies, which have shown promising results with tolerable toxicity profiles in elderly patients.
Paper Details　
Original Abstract of the Article :
Chronic lymphocytic leukemia (CLL) typically affects older patients; administration of traditional cytotoxic therapies in old patients has very modest benefit with no survival improvement. With better understanding of CLL biology, trends are shifting towards the use of targeted therapies. The object...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2020.02.013

データ提供：米国国立医学図書館（NLM）

Targeted Therapies: A New Dawn for Chronic Lymphocytic Leukemia

This study delves into the world of [chronic lymphocytic leukemia (CLL)], a type of cancer that primarily affects [elderly patients]. The researchers provide a comprehensive review of [novel targeted therapies] for [CLL], highlighting their potential to overcome the limitations of traditional [cytotoxic therapies] in this population. The study explores various [targeted agents], including [B-cell receptor (BCR) inhibitors, phosphatidylinositol 3-kinase inhibitors, spleen tyrosine kinase inhibitors, Bcl-2 inhibitors, immunomodulators, and monoclonal antibodies]. These agents have shown promising results in [CLL] treatment, with a favorable [toxicity profile] and improved [clinical outcomes], especially in [elderly patients].

The Power of Precision Medicine: A Personalized Approach to Cancer Care

This study showcases the transformative power of [precision medicine] in [cancer treatment]. By understanding the specific [molecular mechanisms] driving [CLL], doctors can develop more targeted therapies that are more effective and have fewer side effects. This approach is revolutionizing [cancer care] and offers hope for a better future for patients.

Hope on the Horizon: New Treatments for Chronic Lymphocytic Leukemia

This research offers a beacon of hope for individuals battling [CLL]. The development of [novel targeted therapies] is changing the landscape of [CLL] treatment and providing new options for patients, particularly for those who have previously struggled with the side effects of traditional therapies. This research is a reminder that the fight against cancer is ongoing and that new breakthroughs are constantly emerging.

Dr.Camel's Conclusion

This study is like a refreshing spring in the desert of [cancer research]. By targeting the specific roots of [CLL], we can create a more effective and less burdensome path for patients, leading them towards a brighter horizon.

Date :
  1. Date Completed 2021-08-25
  2. Date Revised 2021-08-25
Further Info :

Pubmed ID

32291235

DOI: Digital Object Identifier

10.1016/j.clml.2020.02.013

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.